Biomarkers in localized prostate cancer

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Schroder FH, Hugosson J, Roobol MJ et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 384(9959), 2027–2035 (2014).
  MedlineGoogle Scholar
• 2 Heijnsdijk EA, Wever EM, Auvinen A et al. Quality-of-life effects of prostate-specific antigen screening. N. Engl. J. Med. 367(7), 595–605 (2012).
  Medline CASGoogle Scholar
• 3 Heijnsdijk EA, De Carvalho TM, Auvinen A et al. Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data. J. Natl Cancer Inst. 107(1), 366 (2015).
  Medline CASGoogle Scholar
• 4 Morgan T, Palapattu G, Wei J. Screening for prostate cancer-beyond total PSA, utilization of novel biomarkers. Curr. Urol. Rep. 16(9), 537 (2015).
  Google Scholar
• 5 Louie KS, Seigneurin A, Cathcart P, Sasieni P. Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis. Ann. Oncol. 26(5), 848–864 (2015).
  Medline CASGoogle Scholar
• 6 Ankerst DP, Hoefler J, Bock S et al. Prostate Cancer Prevention Trial Risk Calculator 2.0 for the prediction of low- vs high-grade prostate cancer. Urology 83(6), 1362–1367 (2014).
  MedlineGoogle Scholar
• 7 Tefekli A, Tunc M. Future prospects in the diagnosis and management of localized prostate cancer. ScientificWorldJournal 2013, 347263 (2013).
  MedlineGoogle Scholar
• 8 Lilja H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J. Clin. Invest. 76(5), 1899–1903 (1985).
  Medline CASGoogle Scholar
• 9 Catalona WJ, Smith DS, Ratliff TL et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N. Engl. J. Med. 324(17), 1156–1161 (1991).
  Medline CASGoogle Scholar
• 10 Brawer MK. Prostate-specific antigen: current status. CA Cancer J. Clin. 49(5), 264–281 (1999).
  Medline CASGoogle Scholar
• 11 Vickers AJ, Cronin AM, Aus G et al. A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden. BMC Med. 6, 19 (2008).
  MedlineGoogle Scholar
• 12 Mcvary KT. BPH: epidemiology and comorbidities. Am. J. Manag. Care 12(Suppl. 5), S122–S128 (2006).
  MedlineGoogle Scholar
• 13 Schroder FH, Carter HB, Wolters T et al. Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics. Eur. Urol. 53(3), 468–477 (2008).
  MedlineGoogle Scholar
• 14 Moul JW, Sesterhenn IA, Connelly RR et al. Prostate-specific antigen values at the time of prostate cancer diagnosis in African–American men. JAMA 274(16), 1277–1281 (1995).
  Medline CASGoogle Scholar
• 15 Oesterling JE, Jacobsen SJ, Chute CG et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 270(7), 860–864 (1993).
  Medline CASGoogle Scholar
• 16 Carter HB, Albertsen PC, Barry MJ et al. Early detection of prostate cancer: AUA Guideline. J. Urol. 190(2), 419–426 (2013).
  MedlineGoogle Scholar
• 17 Savblom C, Hallden C, Cronin AM et al. Genetic variation in KLK2 and KLK3 is associated with concentrations of hK2 and PSA in serum and seminal plasma in young men. Clin. Chem. 60(3), 490–499 (2014).
  MedlineGoogle Scholar
• 18 Kundu SD, Roehl KA, Yu X, Antenor JA, Suarez BK, Catalona WJ. Prostate specific antigen density correlates with features of prostate cancer aggressiveness. J. Urol. 177(2), 505–509 (2007).
  Medline CASGoogle Scholar
• 19 Radwan MH, Yan Y, Luly JR et al. Prostate-specific antigen density predicts adverse pathology and increased risk of biochemical failure. Urology 69(6), 1121–1127 (2007).
  MedlineGoogle Scholar
• 20 Corcoran NM, Casey RG, Hong MK et al. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume. BJU Int. 110(1), 36–42 (2012).
  MedlineGoogle Scholar
• 21 Magheli A, Hinz S, Hege C et al. Prostate specific antigen density to predict prostate cancer upgrading in a contemporary radical prostatectomy series: a single center experience. J. Urol. 183(1), 126–131 (2010).
  MedlineGoogle Scholar
• 22 Venderbos LD, Roobol MJ, Bangma CH et al. Rule-based versus probabilistic selection for active surveillance using three definitions of insignificant prostate cancer. World J. Urol. doi:10.1007/s00345-015-1628-y (2015) (Epub ahead of print).
  MedlineGoogle Scholar
• 23 Vickers AJ, Savage C, O'brien MF, Lilja H. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J. Clin. Oncol. 27(3), 398–403 (2009). • This meta-analysis shows that there is insufficient evidence proving that calculation of prostate-specific antigen velocity or doubling time in untreated patients provides additional information with respect to that provided by absolute prostate-specific antigen level alone.
  MedlineGoogle Scholar
• 24 Vickers AJ, Till C, Tangen CM, Lilja H, Thompson IM. An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J. Natl. Cancer Inst. 103(6), 462–469 (2011).
  MedlineGoogle Scholar
• 25 Carter HB, Kettermann A, Ferrucci L, Landis P, Metter EJ. Prostate-specific antigen velocity risk count assessment: a new concept for detection of life-threatening prostate cancer during window of curability. Urology 70(4), 685–690 (2007).
  MedlineGoogle Scholar
• 26 Tosoian JJ, Loeb S, Feng Z et al. Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer. J. Urol. 188(4), 1131–1136 (2012).
  Medline CASGoogle Scholar
• 27 Patel HD, Feng Z, Landis P, Trock BJ, Epstein JI, Carter HB. Prostate specific antigen velocity risk count predicts biopsy reclassification for men with very low risk prostate cancer. J. Urol. 191(3), 629–637 (2014).
  MedlineGoogle Scholar
• 28 Khan MA, Carter HB, Epstein JI et al. Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer? J. Urol. 170(6 Pt 1), 2274–2278 (2003).
  MedlineGoogle Scholar
• 29 Van As NJ, Norman AR, Thomas K et al. Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. Eur. Urol. 54(6), 1297–1305 (2008).
  MedlineGoogle Scholar
• 30 Ng MK, Van As N, Thomas K et al. Prostate-specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA velocity vs PSA doubling time. BJU Int. 103(7), 872–876 (2009).
  Medline CASGoogle Scholar
• 31 Vasarainen H, Salman J, Salminen H et al. Predictive role of free prostate-specific antigen in a prospective active surveillance program (PRIAS). World J. Urol. 33(11), 1735–1740 (2015).
  Medline CASGoogle Scholar
• 32 Hirama H, Sugimoto M, Ito K, Shiraishi T, Kakehi Y. The impact of baseline [-2]proPSA-related indices on the prediction of pathological reclassification at 1 year during active surveillance for low-risk prostate cancer: the Japanese multicenter study cohort. J. Cancer Res. Clin. Oncol. 140(2), 257–263 (2014).
  MedlineGoogle Scholar
• 33 Mikolajczyk SD, Millar LS, Wang TJ et al. A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. Cancer Res. 60(3), 756–759 (2000). •• This article is of considerable interest in that it reports about the potential diagnostic value of a precursor form of prostate-specific antigen.
  Medline CASGoogle Scholar
• 34 Mikolajczyk SD, Marker KM, Millar LS et al. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res. 61(18), 6958–6963 (2001).
  Medline CASGoogle Scholar
• 35 Jansen FH, Van Schaik RH, Kurstjens J et al. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur. Urol. 57(6), 921–927 (2010).
  Medline CASGoogle Scholar
• 36 Sokoll LJ, Sanda MG, Feng Z et al. A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol. Biomarkers Prev. 19(5), 1193–1200 (2010).
  MedlineGoogle Scholar
• 37 Lazzeri M, Haese A, Abrate A et al. Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives,%p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project. BJU Int. 112(3), 313–321 (2013).
  Medline CASGoogle Scholar
• 38 Lazzeri M, Abrate A, Lughezzani G et al. Relationship of chronic histologic prostatic inflammation in biopsy specimens with serum isoform [-2]proPSA (p2PSA),%p2PSA, and prostate health index in men with a total prostate-specific antigen of 4–10 ng/ml and normal digital rectal examination. Urology 83(3), 606–612 (2014).
  MedlineGoogle Scholar
• 39 Bruzzese D, Mazzarella C, Ferro M et al. Prostate health index vs percent free prostate-specific antigen for prostate cancer detection in men with “gray” prostate-specific antigen levels at first biopsy: systematic review and meta-analysis. Transl. Res. 164(6), 444–451 (2014).
  MedlineGoogle Scholar
• 40 Haese A, Graefen M, Steuber T et al. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml. Prostate 49(2), 101–109 (2001).
  Medline CASGoogle Scholar
• 41 Gupta A, Roobol MJ, Savage CJ et al. A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands. Br. J. Cancer 103(5), 708–714 (2010).
  Medline CASGoogle Scholar
• 42 Bryant RJ, Sjoberg DD, Vickers AJ et al. Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study. J. Natl. Cancer Inst. 107(7), (2015). •• This article is of considerable interest in that it proved the predictive value of four kallikrein markers pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens.
  MedlineGoogle Scholar
• 43 Carlsson S, Maschino A, Schroder F et al. Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam. Eur. Urol. 64(5), 693–699 (2013).
  Medline CASGoogle Scholar
• 44 Benchikh A, Savage C, Cronin A et al. A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France. BMC Cancer 10, 635 (2010).
  MedlineGoogle Scholar
• 45 Parekh DJ, Punnen S, Sjoberg DD et al. A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer. Eur. Urol. doi:10.1016/j.eururo.2014.10.021 (2014) (Epub ahead of print).
  MedlineGoogle Scholar
• 46 Stattin P, Vickers AJ, Sjoberg DD et al. Improving the specificity of screening for lethal prostate cancer using prostate-specific antigen and a panel of kallikrein markers: a nested case-control study. Eur. Urol. 68(2), 207–213 (2015).
  Medline CASGoogle Scholar
• 47 Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116(2), 281–297 (2004).
  Medline CASGoogle Scholar
• 48 Casanova-Salas I, Rubio-Briones J, Fernandez-Serra A, Lopez-Guerrero JA. miRNAs as biomarkers in prostate cancer. Clin. Transl. Oncol. 14(11), 803–811 (2012).
  Medline CASGoogle Scholar
• 49 Penney KL, Sinnott JA, Fall K et al. mRNA expression signature of Gleason grade predicts lethal prostate cancer. J. Clin. Oncol. 29(17), 2391–2396 (2011).
  Medline CASGoogle Scholar
• 50 Ren Q, Liang J, Wei J et al. Epithelial and stromal expression of miRNAs during prostate cancer progression. Am. J. Transl. Res. 6(4), 329–339 (2014).
  MedlineGoogle Scholar
• 51 Lichner Z, Ding Q, Samaan S et al. miRNAs dysregulated in association with Gleason grade regulate extracellular matrix, cytoskeleton and androgen receptor pathways. J. Pathol. doi: 10.1002/path.4568 (2015) (Epub ahead of print).
  MedlineGoogle Scholar
• 52 Mahn R, Heukamp LC, Rogenhofer S, Von Ruecker A, Muller SC, Ellinger J. Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology 77(5), 1265 e1269–1265 e1216 (2011).
  Google Scholar
• 53 Shen J, Hruby GW, Mckiernan JM et al. Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer. Prostate 72(13), 1469–1477 (2012).
  Medline CASGoogle Scholar
• 54 Lucarelli G, Rutigliano M, Galleggiante V et al. Metabolomic profiling for the identification of novel diagnostic markers in prostate cancer. Expert Rev. Mol. Diagn. 15(9), 1211–224 (2015).
  Medline CASGoogle Scholar
• 55 Sreekumar A, Poisson LM, Rajendiran TM et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457(7231), 910–914 (2009).
  Medline CASGoogle Scholar
• 56 Melling N, Thomsen E, Tsourlakis MC et al. Overexpression of Enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters. Carcinogenesis 36(11), 1333–1340 (2015).
  Medline CASGoogle Scholar
• 57 Cao DL, Ye DW, Zhu Y, Zhang HL, Wang YX, Yao XD. Efforts to resolve the contradictions in early diagnosis of prostate cancer: a comparison of different algorithms of sarcosine in urine. Prostate Cancer Prostatic Dis. 14(2), 166–172 (2011).
  Medline CASGoogle Scholar
• 58 Lucarelli G, Fanelli M, Larocca AM et al. Serum sarcosine increases the accuracy of prostate cancer detection in patients with total serum PSA less than 4.0 ng/ml. Prostate 72(15), 1611–1621 (2012).
  Medline CASGoogle Scholar
• 59 Lucarelli G, Rutigliano M, Bettocchi C et al. Spondin-2, a secreted extracellular matrix protein, is a novel diagnostic biomarker for prostate cancer. J. Urol. 190(6), 2271–2277 (2013).
  Medline CASGoogle Scholar
• 60 Ferro M, Lucarelli G, Bruzzese D et al. Improving the prediction of pathologic outcomes in patients undergoing radical prostatectomy: the value of prostate cancer antigen 3 (PCA3), prostate health index (phi) and sarcosine. Anticancer Res. 35(2), 1017–1023 (2015).
  MedlineGoogle Scholar
• 61 Lucarelli G, Ditonno P, Bettocchi C et al. Serum sarcosine is a risk factor for progression and survival in patients with metastatic castration-resistant prostate cancer. Future Oncol. 9(6), 899–907 (2013).
  CASGoogle Scholar
• 62 Koutros S, Meyer TE, Fox SD et al. Prospective evaluation of serum sarcosine and risk of prostate cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Carcinogenesis 34(10), 2281–2285 (2013).
  Medline CASGoogle Scholar
• 63 Bussemakers MJ, Van Bokhoven A, Verhaegh GW et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 59(23), 5975–5979 (1999).
  Medline CASGoogle Scholar
• 64 De Kok JB, Verhaegh GW, Roelofs RW et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res. 62(9), 2695–2698 (2002).
  Medline CASGoogle Scholar
• 65 Luo Y, Gou X, Huang P, Mou C. The PCA3 test for guiding repeat biopsy of prostate cancer and its cut-off score: a systematic review and meta-analysis. Asian J. Androl. 16(3), 487–492 (2014).
  MedlineGoogle Scholar
• 66 Hessels D, Smit FP, Verhaegh GW, Witjes JA, Cornel EB, Schalken JA. Detection of TMPRSS2–ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin. Cancer Res. 13(17), 5103–5108 (2007).
  Medline CASGoogle Scholar
• 67 Mehra R, Han B, Tomlins SA et al. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Res. 67(17), 7991–7995 (2007).
  Medline CASGoogle Scholar
• 68 Magi-Galluzzi C, Tsusuki T, Elson P et al. TMPRSS2–ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African–American and Japanese patients. Prostate 71(5), 489–497 (2011).
  Medline CASGoogle Scholar
• 69 Robert G, Jannink S, Smit F et al. Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis. Prostate 73(2), 113–120 (2013).
  Medline CASGoogle Scholar
• 70 Laxman B, Morris DS, Yu J et al. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res. 68(3), 645–649 (2008).
  Medline CASGoogle Scholar
• 71 Salami SS, Schmidt F, Laxman B et al. Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. Urol. Oncol. 31(5), 566–571 (2013).
  Medline CASGoogle Scholar
• 72 Cao DL, Ye DW, Zhang HL, Zhu Y, Wang YX, Yao XD. A multiplex model of combining gene-based, protein-based, and metabolite-based with positive and negative markers in urine for the early diagnosis of prostate cancer. Prostate 71(7), 700–710 (2011).
  Medline CASGoogle Scholar
• 73 Cooperberg MR, Hilton JF, Carroll PR. The CAPRA-S score: a straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer 117(22), 5039–5046 (2011).
  MedlineGoogle Scholar
• 74 Cuzick J, Berney DM, Fisher G et al. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br. J. Cancer 106(6), 1095–1099 (2012).
  Medline CASGoogle Scholar
• 75 Cooperberg MR, Simko JP, Cowan JE et al. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J. Clin. Oncol. 31(11), 1428–1434 (2013).
  Medline CASGoogle Scholar
• 76 Klein EA, Cooperberg MR, Magi-Galluzzi C et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur. Urol. 66(3), 550–560 (2014).
  MedlineGoogle Scholar
• 77 Cullen J, Rosner IL, Brand TC et al. A Biopsy-based 17-gene genomic prostate score predicts recurrence after radical prostatectomy and adverse surgical pathology in a racially diverse population of men with clinically low- and intermediate-risk prostate cancer. Eur. Urol. 68(1), 123–131 (2015). • This article is of interest in that it showed that the Genomic Prostate Score can evaluate the aggressiveness of the cancer.
  MedlineGoogle Scholar
• 78 Heichman KA, Warren JD. DNA methylation biomarkers and their utility for solid cancer diagnostics. Clin. Chem. Lab. Med. 50(10), 1707–1721 (2012).
  Medline CASGoogle Scholar
• 79 Desotelle J, Truong M, Ewald J et al. CpG island hypermethylation frequently silences FILIP1L isoform 2 expression in prostate cancer. J. Urol. 189(1), 329–335 (2013).
  Medline CASGoogle Scholar
• 80 Lee WH, Morton RA, Epstein JI et al. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc. Natl Acad. Sci. USA 91(24), 11733–11737 (1994).
  Medline CASGoogle Scholar
• 81 Stewart GD, Van Neste L, Delvenne P et al. Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC study. J. Urol. 189(3), 1110–1116 (2013).
  MedlineGoogle Scholar
• 82 Partin AW, Van Neste L, Klein EA et al. Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies. J. Urol. 192(4), 1081–1087 (2014).
  MedlineGoogle Scholar
• 83 Litovkin K, Van Eynde A, Joniau S et al. DNA methylation-guided prediction of clinical failure in high-risk prostate cancer. PLoS ONE 10(6), e0130651 (2015).
  MedlineGoogle Scholar
• 84 Daniunaite K, Jarmalaite S, Kalinauskaite N et al. Prognostic value of RASSF1 promoter methylation in prostate cancer. J. Urol. 192(6), 1849–1855 (2014).
  Medline CASGoogle Scholar
• 85 Strand SH, Orntoft TF, Sorensen KD. Prognostic DNA methylation markers for prostate cancer. Int. J. Mol. Sci. 15(9), 16544–16576 (2014).
  Medline CASGoogle Scholar
• 86 Robinson D, Van Allen EM, Wu YM et al. Integrative clinical genomics of advanced prostate cancer. Cell 161(5), 1215–1228 (2015).
  Medline CASGoogle Scholar
• 87 Barbieri CE, Baca SC, Lawrence MS et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat. Genet. 44(6), 685–689 (2012).
  Medline CASGoogle Scholar
• 88 Beltran H, Yelensky R, Frampton GM et al. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur. Urol. 63(5), 920–926 (2013).
  Medline CASGoogle Scholar
• 89 Bancroft EK, Page EC, Castro E et al. Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. Eur. Urol. 66(3), 489–499 (2014).
  MedlineGoogle Scholar